Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2018

View Archived Issues

UCB to acquire Proximagen's midazolam nasal spray

EpimAb and Zhejiang Teruisi Biopharmaceutical enter development collaboration for FIT-012

GlaxoSmithKline describes novel TrpV4 antagonists

New phosphatidylinositol 3-kinase inhibitors identified at Gilead

Kalyra Pharmaceuticals presents novel ERK-1/2 inhibitors

BiopharmaTi divulges novel ketolide antibacterials

Roche discovers new gamma-secretase inhibitors

Sirolimus granted FDA orphan drug designation for the treatment of sickle cell disease

Sage submits NDA for intravenous brexanolone to treat postpartum depression

Prothena discontinues development of NEOD-001

Pfizer receives complete response letter from FDA for trastuzumab biosimilar

Voyager-V1 oncolytic virus under study in patients with solid tumors

FDA grants breakthrough therapy designation to Trumenba for children aged 1-9 years

CBT Pharmaceuticals and CrystalGenomics sign oncology codevelopment agreement

Autolus acquires rights to novel CD19 CAR T-cell therapy from UCL

E.U. approval for Mylotarg with chemotherapy for CD33-positive AML

FDA clears Ultragenyx's IND for phase I/II study of DTX-401 for glycogen storage disease type Ia

Novel PIM/PI3K inhibitor IBL-302 shows promise in preclinical cancer models

Astellas seeks Japanese and U.S. approval for gilteritinib in FLT3 mutation-positive AML

AOBiome Therapeutics initiates phase II study of ammonia oxidizing bacteria product candidate

Connect Biopharmaceuticals files to begin phase I study of CBP-201 in Australia

FDA advisory committee recommends baricitinib 2 mg, rejects 4-mg dose in rheumatoid arthritis

EMA validates type II variation for Keytruda with pemetrexed and chemotherapy in NSCLC

Q Therapeutics and Reprocell create joint venture

FDA issues partial clinical hold for tazemetostat trials

Researchers present potent EGFR T790M-mutant inhibitor E-191

AstraZeneca reports data from ARCTIC study of Imfinzi and tremelimumab in third-line NSCLC

Novel selective estrogen receptor degrader LX-039 selected for clinical development

Atozet launched in Japan

FDA grants fast track designation to AAV-RPGR

Malaria vaccine R-21 shows efficacy in a phase IIa trial

Celgene launches Istodax in Japan

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...